<DOC>
	<DOC>NCT03058809</DOC>
	<brief_summary>This study will access the safety and efficacy of the Viatar™ Oncopheresis System to remove a meaningful quantity of circulating tumor cells from the blood of subjects' with breast, colon or prostate solid tumor cancers in a single treatment. CTC reduction will be measured as the change in circulating tumor cells as determined before and after treatment.</brief_summary>
	<brief_title>Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Confirmed diagnosis of breast, colon or prostate cancer No prior cancer therapy or failed first line therapy &gt;= 25 CTC per 7.5 mL of blood within 1 week prior to oncopheresis treatment &gt; 1 month life expectancy Adequate baseline hematological function as assessed by the following laboratory values: Hemoglobin &gt; 9 g/dl Platelets &gt; 100,000/mm3 WBC &gt; 3,000/mm3 Absolute Neutrophil Count &gt; 1,500/mm3 Coagulation disorders and/or a history of thromboembolic complications, including known hypersensitivity to citrate: e.g., abnormal platelet count, prothrombin time and partial activated thromboplastin time and with a history of deep vein thrombus or pulmonary embolism Patients with known immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>